Dr. Helge Lubenow studied Biology and earned a doctoral degree at the University of Cologne, Germany and Max-Planck-Institute in the field of genetics. Dr. Lubenow has many years of industrial experience in the field of molecular diagnostics and has held positions at QIAGEN, Beiersdorf and Proteomedix in Europe, Asia and the United States. She is an expert for development and market access. She joined Heidelberg Epignostix in June 2025 as CEO.
Dr. Lubenow is a Supervisory Board member of Epigenomics AG, Berlin, Germany; Biofrontera AG, Leverkusen, Germany; Neracare GmbH, Frankfurt am Main, Germany; Human Gesellschaft für Biochemica und Diagnostica mbH, Wiesbaden, Germany and Avelo AG, Schlieren, Switzerland.
Helge Lubenow, Ph.D.
Novel Applications of DNA Methylation-based Tumor Classification in Solid Tumors for Precision Diagnostics
3–4 p.m. Sunday, April 13